Shares of Zogenix, Inc. (NASDAQ:ZGNX) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $24.75.

A number of brokerages have commented on ZGNX. BidaskClub cut shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine cut shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research cut shares of Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $26.00 price target on shares of Zogenix in a research report on Monday, June 26th.

In related news, major shareholder Life Sciences Maste Perceptive acquired 175,653 shares of the business’s stock in a transaction dated Friday, June 30th. The shares were bought at an average price of $14.45 per share, with a total value of $2,538,185.85. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.00% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Zogenix during the second quarter worth $100,000. American International Group Inc. raised its stake in Zogenix by 7.1% in the first quarter. American International Group Inc. now owns 15,278 shares of the company’s stock worth $166,000 after buying an additional 1,010 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Zogenix during the first quarter worth $172,000. Oppenheimer & Co. Inc. acquired a new stake in Zogenix during the first quarter worth $185,000. Finally, Nationwide Fund Advisors raised its stake in Zogenix by 29.5% in the first quarter. Nationwide Fund Advisors now owns 18,748 shares of the company’s stock worth $203,000 after buying an additional 4,266 shares in the last quarter. Institutional investors own 87.29% of the company’s stock.

Zogenix (NASDAQ:ZGNX) opened at 10.25 on Friday. Zogenix has a 12-month low of $7.50 and a 12-month high of $15.40. The company’s market capitalization is $254.62 million. The firm’s 50-day moving average price is $13.43 and its 200 day moving average price is $11.75.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.01. The firm had revenue of $7.10 million for the quarter, compared to the consensus estimate of $3.48 million. Zogenix had a negative net margin of 309.76% and a negative return on equity of 70.75%. The business’s revenue was up 238.1% compared to the same quarter last year. During the same period last year, the company posted ($0.76) EPS. On average, analysts expect that Zogenix will post ($3.63) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/13/zogenix-inc-nasdaqzgnx-receives-average-recommendation-of-hold-from-brokerages.html.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.